A recently concluded clinical trial (TACT) of systemic therapy for coronary disease showed slightly improved cardiovascular function that did not reach statistical significance and is therefore not FDA-approved 18 .
← all excerpts
Reversal of Vascular Calcification and Aneurysms in a Rat Model Using Dual Targeted Therapy with EDTA- and PGG-Loaded Nanoparticles.
1
—
—